PSMC1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1478606	0.58	12/20
SCHEMBL607010	0.56	12/20
SCHEMBL608381	0.53	12/20
SCHEMBL606616	0.51	12/20
SCHEMBL1477637	0.57	11/20
SCHEMBL607972	0.55	11/20
SCHEMBL608782	0.54	11/20
SCHEMBL609278	0.54	11/20
SCHEMBL607553	0.54	11/20
SCHEMBL605822	0.54	11/20
SCHEMBL606932	0.53	11/20
SCHEMBL1477893	0.53	11/20
SCHEMBL608362	0.53	11/20
SCHEMBL608599	0.53	11/20
SCHEMBL1327441	0.53	11/20
SCHEMBL605129	0.52	11/20
SCHEMBL608009	0.52	11/20
SCHEMBL1478157	0.52	11/20
SCHEMBL609081	0.52	11/20
SCHEMBL606926	0.52	11/20

Clinical trials — most relevant to PSMC1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease	PHASE4	UNKNOWN
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer	PHASE2	COMPLETED
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer	PHASE2	COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors	PHASE2	COMPLETED
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma	PHASE2	WITHDRAWN
Bortezomib in Treating Patients With Mantle Cell Lymphoma	PHASE2	COMPLETED
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study	PHASE2	WITHDRAWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM	PHASE1	WITHDRAWN
Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	PHASE1	COMPLETED
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer	PHASE1	COMPLETED
UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies	PHASE1	RECRUITING
Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery	PHASE1	COMPLETED
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment	nan	UNKNOWN
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS)	nan	UNKNOWN
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract	nan	UNKNOWN
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Safety and Tolerability of a Nutritional Formula Designed to Aid in Maintenance of Muscle During Periods of Caloric Restriction in Adults	nan	NOT_YET_RECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Cardiovascular Complications of Carfilzomib Treatment	nan	UNKNOWN
Exploring Novel Biomarkers of ICU-AW in Mechanically Ventilated Children at the Molecular Level	nan	ENROLLING_BY_INVITATION
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
The Pathophysiology of Bortezomib Induced Peripheral Neuropathy	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PSMC1 binder may also engage these)

Protein	Name	Similarity
P62193	—	1.000	P62193 →
Q90732	—	1.000	Q90732 →
P62192	—	1.000	P62192 →
P48601	—	1.000	P48601 →
O16368	—	0.997	O16368 →
Q8SRH0	—	0.997	Q8SRH0 →
Q63347	—	0.997	Q63347 →
P46471	—	0.997	P46471 →
P54778	—	0.996	P54778 →
O42931	—	0.996	O42931 →
Q5R8D7	—	0.995	Q5R8D7 →
Q4R4R0	—	0.995	Q4R4R0 →
PSMC2	26S proteasome regulatory subunit 7	0.995	landscape →
Q41365	—	0.995	Q41365 →
Q9SZD4	—	0.995	Q9SZD4 →
P46472	—	0.995	P46472 →
Q2KIW6	—	0.995	Q2KIW6 →
Q54PN7	—	0.995	Q54PN7 →
P46465	—	0.995	P46465 →
P36612	—	0.995	P36612 →
Q55BV5	—	0.995	Q55BV5 →
Q5E9F9	—	0.995	Q5E9F9 →
Q9SEI2	—	0.994	Q9SEI2 →
P33299	—	0.994	P33299 →
Q01939	—	0.994	Q01939 →
PSMC4	26S proteasome regulatory subunit 6B	0.994	landscape →
O64982	—	0.994	O64982 →
Q63570	—	0.993	Q63570 →
P46466	—	0.993	P46466 →
O88685	—	0.993	O88685 →